CLINICAL TRIALS PROFILE FOR SAXENDA

All Clinical Trials for SAXENDA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02488057 ↗	Improving Beta Cell Function in Mexican American Women With Prediabetes	Completed	Ohio State University	Phase 4	2016-05-01	This study will examine the benefits of weight loss alone or in combination with a GLP1 receptor agonist, liraglutide, on beta cell function in young adult Mexican American (MA) women with prediabetes. The Investigators have chosen to focus on MA women because MA women are at very high risk for progression to diabetes and have not traditionally been involved in weight management studies since they are thought to be difficult to recruit and retain in such programs. However, investigators have had particular success in working with young MA women using specifically developed ethnic and gender conscious programs. Because weight loss does not prevent all progression to diabetes, some participants will receive the diabetes medication, liraglutide, which has been shown to stabilize beta cell function. The study will also interrogate for polymorphisms of known T2DM genes to correlate with beta cell response to weight loss and liraglutide treatment. Additionally, this investigation targets serious health disparities in metabolic disease in a highly vulnerable, rapidly growing population, testing novel gender and culturally focused intervention strategies and identifying genetic biomarkers of response to a pharmacologic intervention that targets the pancreatic ßcell. These results will help to a) understand mechanisms of disease, b) personalize treatment through identification of a high risk group that may be amenable to specific therapy, and c) ultimately, sets the stage for an intervention trial to prevent diabetes, a major chronic and costly disease, in Mexican Americans.
NCT02647944 ↗	Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2015-12-18	This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.
NCT02647944 ↗	Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity	Completed	Novo Nordisk A/S	Phase 2	2015-12-18	This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.
NCT02647944 ↗	Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity	Completed	Mayo Clinic	Phase 2	2015-12-18	This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.
NCT02773355 ↗	Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients	Enrolling by invitation	Novo Nordisk A/S		2016-05-16	This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.
NCT02911818 ↗	Lifestyle Modification and Liraglutide	Completed	Novo Nordisk A/S	Phase 4	2016-09-01	This is a 52 week, single center, open-labeled, randomized controlled trial. A total of 150 subjects with obesity, who are free of types 1 and 2 diabetes, as well as contraindications to weight loss, will be randomly assigned to one of three treatment groups: 1) lifestyle counseling, as currently recommended by the Centers for Medicare and Medicaid Services (CMS) (i.e., CMS-Alone); 2) CMS lifestyle counseling plus liraglutide (i.e., CMS-Liraglutide); or 3) CMS-Liraglutide plus a portion-controlled diet (i.e., Multi-Component Intervention). Subjects in all three groups will have 14 brief (15 minute) lifestyle counseling visits the first 24 weeks, followed by monthly visits in weeks 25-52. This is the schedule and duration of counseling visits recommended by CMS. Counseling sessions will be delivered by a physician, nurse practitioner or registered dietitian (RD) working in consultation with the former providers. Subjects in all three groups also will have brief physician visits at weeks 1, 4, 8, 16, 24, 36, and 52 (total of 7 visits). These visits are needed for subjects in both liraglutide groups to monitor their response to the medication. These visits are included for subjects in CMS-Alone to match the intensity of medical care provided the two other groups. The primary outcome is % reduction in initial body weight, as measured from randomization to week 52. Secondary outcomes include the proportion of participants who at week 52 lose >5%, >10%, and >15% of initial weight, as well as % reduction in weight at week 24 and the proportion of participants who meet the three categorical weight losses at this time. The secondary efficacy measures include changes (from randomization to week 52) in cardiovascular disease (CVD) risk factors, glycemic control, mood, quality of life, eating behavior, appetite, sleep, and satisfaction with weight loss. Safety endpoints will include physical examination, adverse events (AEs), standard laboratory tests, and mental health assessed by the Columbia Suicidality Severity Rating Scale (C-SSRS) and Patient Health Questionnaire (PHQ-9). Statistical Analysis. Using a sample size equation for longitudinal clustered samples, a randomization sample of 50 subjects in CMS-Alone, 50 in CMS-Liraglutide, and 50 in the Multi-Component Intervention provides >80% power to detect the two primary contrasts to be statistically significant. This estimate allows for 20% attrition during the 52-week trial, resulting in approximately 40 treatment completers per group. The ITT longitudinal statistical design will further improve power by allowing the inclusion of available data for non-completers and the adjustment of possible variance reducing baseline covariates.

Clinical Trial Conditions for SAXENDA

Condition Name

Condition Name for SAXENDA
Intervention	Trials
Obesity	25
Weight Loss	3
Obesity, Morbid	2
Parkinson Disease	1

Condition MeSH

Condition MeSH for SAXENDA
Intervention	Trials
Obesity	15
Weight Loss	10
Overweight	3
Obesity, Morbid	2

Clinical Trial Locations for SAXENDA

Trials by Country

Trials by Country for SAXENDA
Location	Trials
United States	33
Mexico	3
United Kingdom	3
Denmark	3
Italy	2

Trials by US State

Trials by US State for SAXENDA
Location	Trials
Minnesota	4
Texas	4
Ohio	3
Pennsylvania	3
California	3

Clinical Trial Progress for SAXENDA

Clinical Trial Phase

Clinical Trial Phase for SAXENDA
Clinical Trial Phase	Trials
PHASE4	3
Phase 4	14
Phase 3	3

Clinical Trial Status

Clinical Trial Status for SAXENDA
Clinical Trial Phase	Trials
Completed	13
Active, not recruiting	7
Recruiting	7

Clinical Trial Sponsors for SAXENDA

Sponsor Name

Sponsor Name for SAXENDA
Sponsor	Trials
Novo Nordisk A/S	13
Mayo Clinic	3
Hvidovre University Hospital	2

Sponsor Type

Sponsor Type for SAXENDA
Sponsor	Trials
Other	40
Industry	16
NIH	5

Last updated: July 24, 2026

Saxenda (liraglutide 3.0 mg) clinical trials update, market analysis, and exclusivity-driven generic risk

Executive summary

Saxenda (liraglutide 3.0 mg injection, once daily) is the branded obesity product in the GLP-1 receptor agonist category built on weight-loss outcomes in a Phase 3 program and supported by ongoing post-marketing evidence. The obesity market now faces accelerated substitution pressure from newer incretin competitors, particularly once-weekly GLP-1s and dual agonists. From an R&D and competitive-landscape standpoint, the near-term outlook for Saxenda is shaped less by first-principles clinical novelty and more by (1) payer preference shifts toward weekly agents, (2) label breadth and durability evidence versus newer products, and (3) the speed at which liraglutide-aligned generics and authorized alternatives can penetrate.

---

What is the latest clinical trial and evidence update for Saxenda (liraglutide 3.0 mg)?

Clinical-evidence anchor. Saxenda’s core clinical package is driven by the SCALE Phase 3 program in obesity and weight management, with outcomes based on weight reduction and categorical response (eg, achieving ≥5% weight loss).

Featured evidence theme (what matters commercially). In the obesity setting, the differentiator is not only average weight loss, but responder rates and durability, plus tolerability for long-term dosing. Saxenda’s place in treatment algorithms is increasingly influenced by real-world adherence and switching patterns to weekly injectables.

What did the Phase 3 SCALE trials establish?

• Population: Adults with obesity (BMI ≥30) or overweight with at least one weight-related comorbidity.
• Design: Randomized, placebo-controlled and longer-term dosing.
• Primary endpoints (typical): Mean weight change and proportion of participants achieving clinically meaningful weight loss.
• Core clinical narrative: Continuous daily dosing produces weight loss over the initial months and requires ongoing therapy for maintenance.

What are the post-marketing and evidence-generation directions?

Market relevance now tracks three evidence lanes:

1. Longer-term durability and adherence in routine practice (persistence on daily injections).
2. Cardiometabolic outcomes for GLP-1 class members and class comparators.
3. Switching and sequencing against weekly GLP-1s (how often patients discontinue daily therapy for weekly regimens).

(No new standalone Phase 3 readout can be asserted here without a specific trial identifier or a confirmed, citable release date. This update focuses on what continues to drive payer and prescribing behavior.)

---

How does Saxenda’s efficacy compare with Wegovy, Zepbound, and other GLP-1/dual agonists?

Short answer. Saxenda is clinically established but faces relative efficacy and convenience disadvantages versus newer weekly incretin therapies in real-world comparative effectiveness. Weekly regimens reduce injection-frequency burden and tend to command formulary momentum.

Key comparison dimensions that influence uptake

• Dose schedule: Daily injection (Saxenda) vs once-weekly dosing (major competitors).
• Responder profiles: Higher average and categorical weight loss with newer agents in many head-to-head and cross-trial comparisons.
• Tolerability profiles: GI adverse events are class-associated; daily dosing can compound adherence friction.
• Therapy sequencing: Clinicians often reserve daily agents for patients not suitable for, not responding to, or not covered by preferred weekly options.

Commercial implication

Saxenda’s market trajectory is typically shaped by:

• how rapidly payers steer to preferred tier weekly products, and
• how often patients cycle back when weekly options are limited by coverage, supply, or intolerance.

---

What is Saxenda’s market size, sales trajectory, and revenue exposure by channel?

Featured snapshot (commercial reality). Saxenda remains a meaningful legacy brand in US obesity pharmacotherapy, but category growth is increasingly captured by newer GLP-1s and dual agonists. As a result, Saxenda’s topline is pressured by:

• formulary status changes,
• substitution at initiation, and
• reduced patient persistence as weekly options become first-line in managed care.

Channel dynamics that typically determine Saxenda performance

• Commercial pharmacy vs specialty distribution: GLP-1 obesity products are mostly specialty-channel managed.
• Formulary access: Prior authorization and step therapy are major levers.
• Coverage ceilings and refill constraints: These can disproportionately affect daily products where adherence is more sensitive to copays and persistence.

(A numeric sales forecast cannot be stated here without current brand revenue inputs from audited/recognized sources. The analysis below is structured as drivers and scenario logic rather than unsupported dollar figures.)

---

What are the pricing and payer dynamics affecting Saxenda’s uptake and switching?

Payer mechanics.

• Prior authorization criteria: Typically require BMI/weight-loss history and may demand documented comorbidity.
• Step edits: Many plans prefer weekly agents, treating Saxenda as a later-line option.
• Rebates and net price: GLP-1 class products are subject to heavy contracting. Net pricing can differ materially from list price.

What drives payer preference away from daily therapy

• Simplified patient management: Weekly dosing reduces program complexity for payers.
• Better adherence in practice: Injection frequency correlates with persistence.
• Clinical outcomes in trial-to-real-world translation: Newer agents often present stronger weight loss distributions and higher responder proportions.

---

When does Saxenda lose exclusivity, and what generic or biosimilar entry risks exist?

Core concept for generics risk. Exclusivity in the obesity space hinges on a mix of:

• regulatory exclusivities tied to approval pathways,
• Orange Book-listed patents that can block generic entry, and
• composition-of-matter and formulation patents that may extend effective exclusivity.

Actionable market-risk lens. For Saxenda, generic and biosimilar risk depends on:

1. availability of an approved generic liraglutide product aligned to the 3.0 mg dose and delivery system,
2. whether patent litigation or settlements permit “carve-out” launch dates, and
3. whether entry would require significant formulation/manufacturing work that faces patent barriers.

What patent estate questions usually decide the timing

• Which patents are listed for Saxenda in the FDA Orange Book (composition, formulation, method-of-use).
• Whether any active Orange Book litigation has defined launch carve-outs.
• Whether a generic applicant faces Paragraph IV exposure with settlement agreements.

(This section cannot enumerate specific patent numbers, expiration dates, and Orange Book status without citing an Orange Book extract or a litigation docket. The analysis stays focused on risk drivers rather than unverified dates.)

---

What patent litigation or settlement activity affects Saxenda generic entry?

What usually matters in practice

• Paragraph IV filings and whether they triggered a 30-month stay.
• Injunction risk based on asserted patents and claim scope.
• Settlement terms defining “launch on” dates or “carve-out” claims.

(No specific litigation events can be listed without sourced case details or docket citations.)

---

What is the Orange Book status of Saxenda (liraglutide 3.0 mg), and what patents protect it?

How this is used commercially

• To assess likelihood of generic launch windows.
• To structure licensing or clearance strategies.
• To evaluate whether formulation or method-of-use claims can block non-infringing alternatives.

Typical patent categories for GLP-1 obesity brands

• Composition-of-matter for the active ingredient.
• Formulation/device claims for the injection.
• Method-of-use claims for obesity treatment regimens and titration/dosing approaches.

(No specific Orange Book listings can be provided without the underlying patent/patent-registration dataset.)

---

How strong is the patent estate for Saxenda versus competitive GLP-1 obesity brands?

Strength is assessed along three axes

1. Count and maturity: how many Orange Book patents remain in force near the horizon.
2. Claim coverage breadth: whether patents cover the dose, delivery, and dosing regimen.
3. Litigation signal: whether patents have held up in litigation or have been narrowed/invalidated.

Commercial comparison logic Saxenda’s competitive environment is increasingly influenced by the broader category’s shift. Even if Saxenda’s patent position is stable, its practical growth depends on payer routing toward newer weekly competitors.

---

Which companies are competing with Saxenda in obesity treatment and how do they differ?

Competitive cluster

• Once-weekly GLP-1 obesity agents (high payer preference).
• Dual incretin agents (compete on higher efficacy and rapid market capture).
• Adjacent weight-loss pharmacotherapies (smaller share, different mechanisms).

Business implication Saxenda faces competitive displacement even where it remains clinically appropriate, because payers and PBMs optimize for net cost per responder and ease of use.

(Company-by-company market share cannot be quantified here without a cited dataset.)

---

What manufacturing and formulation IP barriers matter for liraglutide generics targeting Saxenda?

Main practical hurdles

• Replicating the branded injection’s stability, concentration, and delivery performance.
• Manufacturing process controls for peptide synthesis and aseptic fill-finish.
• Ensuring non-infringement of formulation and device-associated claims.

How this affects timelines Even where composition barriers are cleared, formulation and process IP can delay approvals or increase launch costs via design-around requirements.

---

What is the regulatory status of Saxenda and what FDA milestones drive competition?

Approval status (high level). Saxenda is FDA-approved for chronic weight management, supported by its clinical evidence and ongoing safety reporting.

Regulatory milestones that influence market

• Changes to labeling and dosing guidance.
• REMS (if applicable), safety communications, and post-marketing requirements.
• Generic and biosimilar application approvals and exclusivity determinations.

(No specific current FDA labeling revision dates or REMS updates are asserted without a sourced FDA filing history extract.)

---

Market projection scenarios for Saxenda: base, downside, and upside

Base case (most consistent with current category dynamics)

• Continued category growth favors newer weekly and dual agents.
• Saxenda maintains a legacy base where daily dosing is tolerated and where coverage remains stable.
• Growth is limited and share erodes through substitution at initiation.

Downside case (most likely with intensified formulary controls)

• More plans move Saxenda to a non-preferred tier or require higher step therapy.
• Higher discontinuation rates due to patient preference and adherence tradeoffs.
• Net price pressure from contracting leverage increases volatility.

Upside case (conditions that can preserve share)

• Payer revisions include broader coverage access or tighter step edits that keep daily agents in play.
• Evidence updates emphasize a subgroup advantage where daily dosing is clinically preferred.
• Competitive supply disruptions temporarily raise demand for older, available daily products.

---

Key Takeaways

• Saxenda’s clinical foundation is strong, but market growth is constrained by substitution toward once-weekly incretin and dual agonist therapies.
• The practical competitive battleground is payer routing, adherence economics, and responder value, not only trial efficacy averages.
• Generic entry timing depends on the Orange Book patent constellation, Paragraph IV litigation posture, and formulation/device non-infringement, which determine whether launches face 30-month stays or settlement carve-outs.
• Near-term market outcomes are dominated by formulary policy and switching behavior within obesity pharmacotherapy.

---

FAQs

1) Why do payers prefer weekly obesity GLP-1 products over Saxenda?
Because weekly dosing typically improves persistence and simplifies patient management, lowering real-world drop-off versus daily therapy.

2) Does Saxenda still have a role if patients can access newer GLP-1s?
Yes, in coverage-constrained, intolerance-related, or clinical sequencing scenarios where daily dosing remains acceptable and accessible.

3) What evidence is most likely to keep clinicians prescribing Saxenda?
Durability of response in routine use, tolerability management, and patient-level adherence outcomes compared with alternatives.

4) How should investors model Saxenda’s revenue under patent expiration and generic entry?
Use exclusivity and litigation-driven launch timing, then apply fast share capture assumptions typical for obesity GLP-1 markets once barriers clear, tempered by persistence/adherence differences.

5) What are the biggest non-clinical risks to Saxenda’s market position?
Formulary exclusion, prior authorization tightening, net price pressure from competitive contracting, and switching behavior to preferred weekly therapies.

---

References

1. FDA (U.S. Food and Drug Administration). FDA Drug Approval and Labeling information for Saxenda (liraglutide).
2. FDA. Orange Book database for Saxenda (liraglutide) listings and exclusivity information.
3. Clinical trial publications for liraglutide 3.0 mg in the SCALE program (obesity Phase 3).